Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Consistently, the HCA/HCC lesions developed in the G6Pase-α-deficient livers display marked accumulation of p62 aggregates and phosphorylated p62 along with activation of Nrf2 and mTORC1 signaling.
|
31735334 |
2020 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Collectively, we demonstrated that SLC27A5 acts as a novel tumor suppressor by suppressing TXNRD1 expression via the KEAP1/NRF2 pathway in HCC.
|
31367013 |
2020 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Correction: Camptothecin suppresses NRF2-ARE activity and sensitises hepatocellular carcinoma cells to anticancer drugs.
|
31350527 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma.
|
30909929 |
2019 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
<i>Nrf2-lncRNA</i> levels correlated with the recurrence-free postsurgery survival rate of patients with hepatocellular carcinoma.
|
30897343 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Using microarray, quantitative reverse transcription-PCR, and RNA-seq technologies, we examined the gene expression induced by PB125 in HepG2 (hepatocellular carcinoma) cells, including canonical Nrf2-regulated genes, noncanonical Nrf2-regulated genes, and genes which appear to be regulated by non-Nrf2 mechanisms.
|
31058853 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Therefore, we conducted this research to examine the therapeutic effects of nicotinamide against hepatocellular carcinoma (HCC) both in vivo and in vitro through affecting IGF-1 and the balance between PKB and Nrf2.
|
30784932 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: A novel mechanism for host-microbe survival and HCC development in liver cirrhosis.
|
31386899 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, the present investigation suggest that the NRAL/miR-340-5p/Nrf2 axis mediates cisplatin resistance in HCC, which may provide novel targets for overcoming cisplatin resistance in hepatocellular carcinoma cells.
|
30030687 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, phosphorylation of KHK-A S80 and p62 S28 and nuclear accumulation of Nrf2 are positively correlated in human HCC specimens and with poor prognosis of patients with HCC.
|
31032410 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Collectively, our results indicate the presence of a novel NRF2 SUMOylation-mediated signaling process that maintains HCC tumorigenesis in normal conditions and in response to metabolic stress.
|
31546024 |
2019 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Nrf2 and NF-κB are the key transcription factors that regulate oxidative stress and inflammation, therefore we assessed whether TX modulate these pathways and its downstream proteins in HuH-7 hepatocarcinoma cells.
|
30389603 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
GSH depletion caused by GSTZ1 deficiency elevates oxidative stress, thus constitutively activating the NRF2 antioxidant response pathway and accelerating HCC progression.
|
31666108 |
2019 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Manipulation of levels of GSH and Nrf2 in HepG2 cells confirmed that both molecules mediate the protective effects of SFN against H<sub>2</sub>O<sub>2</sub>.
|
30940595 |
2019 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ATO reduced Nrf2 and antioxidant enzyme superoxide dismutase-2 (SOD2) expression in human hepatocarcinoma HepG2 cells.
|
31423616 |
2019 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that curcumin may induce ROS scavenging by upregulating Nrf2 and GSH, thus inhibiting HIF-1<i>α</i> stabilization to suppress CTGF expression to exhibit its protection on HCC.
|
30800209 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In human hepatoma HepG2 cells, electrophoretic mobility shift assay (EMSA) was used to determine the affinity of nuclear factor-E2-related factor (Nrf2) binding to MRP4 promoter.
|
31637886 |
2019 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Nrf2-mediated anti-oxidant effects contribute to suppression of non-alcoholic steatohepatitis-associated hepatocellular carcinoma in murine model.
|
30279623 |
2018 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Combination therapy in a TAA-induced HCC rat model was more effective than 5-FU or Vit D through the modulation of TGF-β1, caspase-3, and NrF2 expressions.
|
30205014 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These emerging molecular mechanisms and the therapeutic perspective of targeting Nrf2-p62 interaction in HCC are discussed in this paper along with the prognostic value of autophagy in this type of cancer.
|
29274776 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
All of our data confirmed that oxidative stress-mediated mitochondrial apoptosis (especially the Nrf-2/HO-1 pathway) is responsible for 5h2c-induced HCC damage.
|
30055129 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This review summarizes the role and mechanism(s) of action of Nrf2 dysregulation in HCC and therapeutic options that can be employed to modulate this transcription factor.
|
30513925 |
2018 |
Liver carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
PCK1 Downregulation Promotes TXNRD1 Expression and Hepatoma Cell Growth via the Nrf2/Keap1 Pathway.
|
30619751 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In this current review, we discussed recent advances in the function and principal mechanisms by regulating Nrf2 in liver diseases, including acute liver failure, hepatic ischemia-reperfusion injury (IRI), alcoholic liver disease (ALD), viral hepatitis, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC).
|
30670963 |
2018 |
Liver carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This review summarizes the recent understanding of the involvement of Nrf2 in the chemoresistance of liver cancer, its target proteins, expression regulation and potential Nrf2 inhibitors that sensitize chemotherapy drugs in HCC.
|
29223570 |
2018 |